p53 codon 72 polymorphism as a progression index for bladder cancer.
The aim of this study was to calculate the positive predictive value (PPV)             and negative predictive value (NPV) to determine whether p53 codon 72 can be used             as a bladder cancer management index. Ninety-six patients diagnosed with bladed             cancer and two control groups of 427 randomly sampled community participants and             142 non-cancerous individuals without a prior history of cancer were enrolled.             After preliminary analysis, the convergent validity resulted in 96 patients from             this study and 129 patients from our previous study. Results showed that these             two groups were of the same population, and could be merged into one case group.             Logistic regression showed that the Pro/Pro genotype was not statistically significantly             associated with bladder cancer incidence using each sample set after adjustment             by age and gender. Moreover, the Pro/Pro genotype was not associated with high-grade             tumors (P=0.078), but was highly correlated to muscle-invasive tumors (P=0.002).             Pro/Pro genotype carriers were estimated to have a 3.36-fold higher risk to develop             invasive tumors compared to non-carriers. The NPV of the Pro/Pro genotype for             invasive tumors was 88.00%, and the PPV was 31.91%. By Cox regression analysis,             high-grade tumors were associated with recurrence (P=0.020, OR=1.83), whereas             invasive tumors were associated with cancer-related death (P<0.001, OR=2.87).             p53 codon 72 polymorphism is associated with bladder cancer progression rather             than incidence and prognosis. The Pro/Pro genotype in p53 codon 72 polymorphism             shows a high NPV for bladder cancer progression, thus, it can be used clinically             as a progression index in bladder cancer management.
Department of Urology, E-DA Hospital/I-SHOU University, Kaohsiung, Taiwan, ROC.
Hung-Yu
HY
Lin
Chun-Hsiung
CH
Huang
Tsan-Jung
TJ
Yu
Wen-Jen
WJ
Wu
Ming-Chang
MC
Yang
For-Wey
FW
Lung
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003062:Codon; D018450:Disease Progression; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D016016:Proportional Hazards Models; D018570:Risk Assessment; D012307:Risk Factors; D013624:Taiwan; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology
D014408:Biomarkers, Tumor; D003062:Codon; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53